<DOC>
	<DOCNO>NCT00001113</DOCNO>
	<brief_summary>To evaluate safety toxicity combination therapy AIDS-associated Kaposi 's sarcoma zidovudine ( AZT ) two kind interferon alpha . The two kind interferon alpha ( IFN-A ) interferon alpha-2A ( recombinant ) ( IFN-A2A ) . To define pharmacokinetics AZT IFN-A AZT IFN-A2A give combination . To define maximum tolerate dose ( MTD ) drug combination define dos use Phase II trial . AZT find effective effect HIV vitro ( test tube ) interferon show antiviral antitumor effect Kaposi 's sarcoma . It reasonable assume synergism enhance antitumor response may see combination therapy . A study evaluate safety effectiveness AZT combination IFN-A2A warrant .</brief_summary>
	<brief_title>A Study AZT Plus Human Interferon Alpha Treatment AIDS-Related Kaposi 's Sarcoma</brief_title>
	<detailed_description>AZT find effective effect HIV vitro ( test tube ) interferon show antiviral antitumor effect Kaposi 's sarcoma . It reasonable assume synergism enhance antitumor response may see combination therapy . A study evaluate safety effectiveness AZT combination IFN-A2A warrant . Patients randomized receive IFN-A IFN-A2A intramuscular injection combine AZT orally daily 8 week . Two cohort 4 patient enter dose level . Patients enter next dose level patient complete 3 week treatment . AZT escalate unacceptable toxicity ( grade 2 = &gt; 3 patient &gt; grade 2 patient ) ; subsequent increase IFN-A IFN-A2A permit , AZT dose remain fixed . The MTD give IFN-A IFN-A2A dose level define grade 3 toxicity hemoglobin grade 2 toxicity parameter 3 6 patient . Once MTD reach , enrollment high dose level . Patients follow every week vital sign hematologic study . Patients tolerate combination may continue therapy 1 year dose end 8th week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Patient must histologically confirm diagnosis Kaposi 's sarcoma . Positive antibody HIV confirm ELISA Western blot serum . Exclusion Criteria Active drug alcohol abuse . Coexisting Condition : Patients follow complication exclude : Active opportunistic infection require ongoing therapy . Pneumocystis carinii pneumonia ( PCP ) unless recover must therapy within 90 day prior study . Clinically significant cardiac disease , include history myocardial infarction arrhythmia . Concurrent neoplasms basal cell carcinoma skin . Known sensitivity polymycin neomycin . Patients follow complication exclude : Active opportunistic infection require ongoing therapy . Pneumocystis carinii pneumonia ( PCP ) unless recover must therapy within 90 day prior study . Clinically significant cardiac disease , include history myocardial infarction arrhythmia . Concurrent neoplasms basal cell carcinoma skin . Known sensitivity polymycin neomycin . Prior Medication : Excluded : Any prior zidovudine ( AZT ) interferon alpha protocol participation . Excluded within 30 day study entry : Immunomodulating agent . Other drug cause neutropenia significant nephrotoxicity , systemic antiinfectives . Excluded within 90 day study entry : Antiretroviral agent . Treatment Pneumocystis carinii pneumonia ( PCP ) . Prior Treatment : Excluded within 30 day study entry : Radiation therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Interferon Alfa-2a</keyword>
	<keyword>Sarcoma , Kaposi</keyword>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Interferon Type I</keyword>
</DOC>